完美移植 - Suppr | 超能文献

The Perfect Transplant.

作者信息

Holtan Shernan G

机构信息

Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota.

出版信息

Biol Blood Marrow Transplant. 2017 Jul;23(7):1044-1045. doi: 10.1016/j.bbmt.2017.05.010. Epub 2017 May 11.

DOI:10.1016/j.bbmt.2017.05.010

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

The Perfect Transplant.完美移植

Biol Blood Marrow Transplant. 2017 Jul;23(7):1044-1045. doi: 10.1016/j.bbmt.2017.05.010. Epub 2017 May 11.

2

Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.供者类型和疾病风险预测异基因造血细胞移植的成功：采用改良复合终点对 613 例成人造血细胞移植受者的单中心分析。

Biol Blood Marrow Transplant. 2017 Dec;23(12):2192-2198. doi: 10.1016/j.bbmt.2017.08.030. Epub 2017 Aug 30.

3

Prognostic factors on graft-versus-host disease-free and relapse-free survival after allogeneic hematopoietic stem cell transplantation for adults with acute leukemia.成人急性白血病异基因造血干细胞移植后无移植物抗宿主病和无复发生存的预后因素

Leuk Res. 2017 Aug;59:1-7. doi: 10.1016/j.leukres.2017.05.011. Epub 2017 May 12.

4

Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.预测异基因造血细胞移植后无移植物抗宿主病、无复发生存的因素：来自单一中心的多变量分析

Biol Blood Marrow Transplant. 2016 Aug;22(8):1403-1409. doi: 10.1016/j.bbmt.2016.04.006. Epub 2016 Apr 14.

5

Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma.预测复发或难治性非霍奇金淋巴瘤患者接受异基因造血干细胞移植后移植物抗宿主病和无复发生存的风险因素。

Ann Hematol. 2019 Jul;98(7):1743-1753. doi: 10.1007/s00277-019-03714-x. Epub 2019 May 14.

6

Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.部分T细胞清除可改善异基因造血干细胞移植后无移植物抗宿主病、无复发的复合终点生存率。

Leuk Lymphoma. 2018 Mar;59(3):590-600. doi: 10.1080/10428194.2017.1344844. Epub 2017 Jul 6.

7

Refractory Graft-Versus-Host Disease-Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success.无移植物抗宿主病、无复发的难治性存活率作为评估长期移植成功的准确且易于计算的终点。

Biol Blood Marrow Transplant. 2018 Jul;24(7):1521-1526. doi: 10.1016/j.bbmt.2018.02.004. Epub 2018 Feb 21.

8

Current Graft-versus-Host Disease-Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant.当前无移植物抗宿主病、无复发生存：一种更好地定义异基因移植后疗效的动态终点。

Biol Blood Marrow Transplant. 2017 Jul;23(7):1208-1214. doi: 10.1016/j.bbmt.2017.02.022. Epub 2017 Apr 5.

9

Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.对于急性白血病患者，GVHD 无复发生存率优于 G-BM 到 G-PBSC 移植物，这与同种异体移植中更高的髓系抑制细胞含量有关。

J Hematol Oncol. 2017 Jul 4;10(1):135. doi: 10.1186/s13045-017-0503-2.

10

[Graft-versus-host disease-free, and relapse-free survival in Japanese patients with hematological malignancies].[日本血液系统恶性肿瘤患者的无移植物抗宿主病和无复发生存率]

Rinsho Ketsueki. 2018;59(8):1101-1107. doi: 10.11406/rinketsu.59.1101.

引用本文的文献

1

Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease?间充质基质细胞：急性移植物抗宿主病的机制是什么？

Biomedicines. 2017 Jul 1;5(3):39. doi: 10.3390/biomedicines5030039.